In the phase 3 DRIVE-AHEAD trial among HIV treatment-naive adults, a once-daily, single-tablet regimen of doravirine-lamivudine-tenofovir demonstrated non-inferior efficacy and a superior safety profile for neuropsychiatric events and fasting lipids compared with efavirenz-emtricitabine-tenofovir. Researchers presented results at CROI 2018 that characterized the effects of DOR/3TC/TDF in several subgroups (gender, race/ethnicity, hepatitis co-infection and baseline CD4+ T-cell counts). Across
MARCH 7, 2018